JPWO2022059763A1 - - Google Patents

Info

Publication number
JPWO2022059763A1
JPWO2022059763A1 JP2022550623A JP2022550623A JPWO2022059763A1 JP WO2022059763 A1 JPWO2022059763 A1 JP WO2022059763A1 JP 2022550623 A JP2022550623 A JP 2022550623A JP 2022550623 A JP2022550623 A JP 2022550623A JP WO2022059763 A1 JPWO2022059763 A1 JP WO2022059763A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022550623A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022059763A1 publication Critical patent/JPWO2022059763A1/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022550623A 2020-09-17 2021-09-17 Pending JPWO2022059763A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020156457 2020-09-17
PCT/JP2021/034211 WO2022059763A1 (ja) 2020-09-17 2021-09-17 オートファジー活性化剤

Publications (1)

Publication Number Publication Date
JPWO2022059763A1 true JPWO2022059763A1 (https=) 2022-03-24

Family

ID=80776039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022550623A Pending JPWO2022059763A1 (https=) 2020-09-17 2021-09-17

Country Status (5)

Country Link
JP (1) JPWO2022059763A1 (https=)
KR (1) KR20230051238A (https=)
CN (1) CN116437912A (https=)
TW (1) TW202228676A (https=)
WO (1) WO2022059763A1 (https=)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06271466A (ja) * 1993-03-23 1994-09-27 Asahi Chem Ind Co Ltd 神経成長因子活性増強剤
JP2013245194A (ja) * 2012-05-25 2013-12-09 Lion Corp 経口投与組成物
JP2018510902A (ja) * 2015-04-08 2018-04-19 バイオメンディクス エルエルシー 創傷治癒調節のための製剤および方法
JP2018080204A (ja) * 2011-08-01 2018-05-24 株式会社林原 α−グルコシルヘスペリジンの結晶とその用途
WO2018173653A1 (ja) * 2017-03-24 2018-09-27 株式会社林原 オートファジー誘導剤とその用途
JP2019011254A (ja) * 2017-06-29 2019-01-24 ちふれホールディングス株式会社 表皮肥厚抑制剤
JP2019081718A (ja) * 2017-10-30 2019-05-30 日光ケミカルズ株式会社 ヒアルロン酸合成酵素発現促進剤
JP2019529514A (ja) * 2015-10-05 2019-10-17 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーフラックス及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
JP2021098668A (ja) * 2019-12-23 2021-07-01 株式会社アイ・ティー・オー 細胞送達用キャリア

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4111856B2 (ja) * 2002-04-12 2008-07-02 昭和電工株式会社 安定化されたアスコルビン酸誘導体
KR20170025604A (ko) * 2015-08-31 2017-03-08 연세대학교 원주산학협력단 아스코르브산 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 퇴행성 신경질환 치료용 약학적 조성물

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06271466A (ja) * 1993-03-23 1994-09-27 Asahi Chem Ind Co Ltd 神経成長因子活性増強剤
JP2018080204A (ja) * 2011-08-01 2018-05-24 株式会社林原 α−グルコシルヘスペリジンの結晶とその用途
JP2013245194A (ja) * 2012-05-25 2013-12-09 Lion Corp 経口投与組成物
JP2018510902A (ja) * 2015-04-08 2018-04-19 バイオメンディクス エルエルシー 創傷治癒調節のための製剤および方法
JP2019529514A (ja) * 2015-10-05 2019-10-17 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーフラックス及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
WO2018173653A1 (ja) * 2017-03-24 2018-09-27 株式会社林原 オートファジー誘導剤とその用途
JP2019011254A (ja) * 2017-06-29 2019-01-24 ちふれホールディングス株式会社 表皮肥厚抑制剤
JP2019081718A (ja) * 2017-10-30 2019-05-30 日光ケミカルズ株式会社 ヒアルロン酸合成酵素発現促進剤
JP2021098668A (ja) * 2019-12-23 2021-07-01 株式会社アイ・ティー・オー 細胞送達用キャリア

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHOI, Y. K. ET AL.: "L-Ascorbic Acid Inhibits Breast Cancer Growth by Inducing IRE/JNK/CHOP-Related Endoplasmic Reticulum", NUTRIENTS, vol. Vo.12(5):1351, JPN6021043603, 8 May 2020 (2020-05-08), pages 1 - 19, ISSN: 0005764953 *
FUKUI, M. ET AL.: "Mechanism of Ascorbate-Induced Cell Death in Human Pancreatic Cancer Cells: Role of Bcl-2, Beclin 1", PLANTA MEDICA, vol. 81, JPN6021043604, 2015, pages 838 - 846, ISSN: 0005764954 *

Also Published As

Publication number Publication date
TW202228676A (zh) 2022-08-01
KR20230051238A (ko) 2023-04-17
WO2022059763A1 (ja) 2022-03-24
CN116437912A (zh) 2023-07-14

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
JPWO2022059767A1 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260106